(ONC) BeiGene - Overview
Stock: BTK-Inhibitor, Anti-PD-1, PARP-Inhibitor, Bcl-2-Inhibitor, Bispecific-Antibody
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 44.3% |
| Relative Tail Risk | -6.75% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.07 |
| Alpha | 45.75 |
| Character TTM | |
|---|---|
| Beta | 0.485 |
| Beta Downside | 0.905 |
| Drawdowns 3y | |
|---|---|
| Max DD | 51.45% |
| CAGR/Max DD | 0.26 |
Description: ONC BeiGene January 29, 2026
BeOne Medicines AG (formerly BeiGene) is a Basel-based oncology biotech that develops and commercializes small-molecule and antibody-based therapies across blood and solid cancers. Its approved, commercial-stage portfolio includes BRUKINSA (BTK inhibitor), TEVIMBRA (PD-1 antibody) and PARTRUVIX (PARP1/2 inhibitor), while its clinical-stage pipeline spans more than 20 candidates targeting Bcl-2, BTK degradation, TIGIT, EGFR, KRAS, PRMT5 and several bispecific/ADC formats. The company maintains strategic R&D collaborations with Amgen, BMS, Novartis and others, and operates globally in the U.S., China and Europe.
In its most recent fiscal quarter (Q3 2024), BeOne reported total revenue of $2.1 billion, a 15 % year-over-year increase driven primarily by BRUKINSA sales of $620 million and expanding TEVIMBRA uptake in the Chinese market. The oncology biotech sector is currently valued at roughly $300 billion worldwide and is projected to grow at an 8 % CAGR through 2028, supported by rising cancer incidence and increasing adoption of targeted immunotherapies. BTK inhibitors alone account for an estimated $2.5 billion market size, suggesting that BeOne’s BTK platform could capture a meaningful share if its next-generation BTK degrader (BGB-16673) demonstrates superiority in upcoming Phase III data.
Given the breadth of BeOne’s pipeline and the favorable macro-trend in oncology therapeutics, a deeper quantitative dive (e.g., discounted cash-flow scenarios, comparable-company multiples, and pipeline risk-adjusted valuation) is warranted; ValueRay’s analytics platform can help you model those assumptions efficiently.
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income: 68.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA 23.94 > 1.0 |
| NWC/Revenue: 66.28% < 20% (prev 56.87%; Δ 9.41% < -1%) |
| CFO/TA 0.10 > 3% & CFO 785.4m > Net Income 68.5m |
| Net Debt (-3.02b) to EBITDA (301.3m): -10.01 < 3 |
| Current Ratio: 2.39 > 1.5 & < 3 |
| Outstanding Shares: last quarter (114.5m) vs 12m ago 9.38% < -2% |
| Gross Margin: 86.19% > 18% (prev 0.84%; Δ 8535 % > 0.5%) |
| Asset Turnover: 73.87% > 50% (prev 56.88%; Δ 16.99% > 0%) |
| Interest Coverage Ratio: -10.73 > 6 (EBITDA TTM 301.3m / Interest Expense TTM -15.5m) |
Altman Z'' -3.13
| A: 0.43 (Total Current Assets 5.66b - Total Current Liabilities 2.37b) / Total Assets 7.63b |
| B: -1.10 (Retained Earnings -8.39b / Total Assets 7.63b) |
| C: 0.02 (EBIT TTM 166.7m / Avg Total Assets 6.73b) |
| D: -2.42 (Book Value of Equity -8.49b / Total Liabilities 3.50b) |
| Altman-Z'' Score: -3.13 = D |
Beneish M -2.98
| DSRI: 0.95 (Receivables 863.3m/603.0m, Revenue 4.97b/3.32b) |
| GMI: 0.97 (GM 86.19% / 83.74%) |
| AQI: 0.74 (AQ_t 0.03 / AQ_t-1 0.04) |
| SGI: 1.50 (Revenue 4.97b / 3.32b) |
| TATA: -0.09 (NI 68.5m - CFO 785.4m) / TA 7.63b) |
| Beneish M-Score: -2.98 (Cap -4..+1) = A |
What is the price of ONC shares?
Over the past week, the price has changed by +3.98%, over one month by +10.48%, over three months by +6.49% and over the past year by +54.64%.
Is ONC a buy, sell or hold?
- StrongBuy: 15
- Buy: 8
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the ONC price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 404.2 | 14.2% |
| Analysts Target Price | 404.2 | 14.2% |
| ValueRay Target Price | 383.3 | 8.3% |
ONC Fundamental Data Overview February 02, 2026
P/E Forward = 42.9185
P/S = 7.5745
P/B = 9.3793
Revenue TTM = 4.97b USD
EBIT TTM = 166.7m USD
EBITDA TTM = 301.3m USD
Long Term Debt = 139.6m USD (from longTermDebt, last quarter)
Short Term Debt = 829.0m USD (from shortTermDebt, last quarter)
Debt = 1.02b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -3.02b USD (from netDebt column, last quarter)
Enterprise Value = 34.65b USD (37.67b + Debt 1.02b - CCE 4.04b)
Interest Coverage Ratio = -10.73 (Ebit TTM 166.7m / Interest Expense TTM -15.5m)
EV/FCF = 74.58x (Enterprise Value 34.65b / FCF TTM 464.6m)
FCF Yield = 1.34% (FCF TTM 464.6m / Enterprise Value 34.65b)
FCF Margin = 9.34% (FCF TTM 464.6m / Revenue TTM 4.97b)
Net Margin = 1.38% (Net Income TTM 68.5m / Revenue TTM 4.97b)
Gross Margin = 86.19% ((Revenue TTM 4.97b - Cost of Revenue TTM 686.7m) / Revenue TTM)
Gross Margin QoQ = 86.09% (prev 87.49%)
Tobins Q-Ratio = 4.54 (Enterprise Value 34.65b / Total Assets 7.63b)
Interest Expense / Debt = 1.79% (Interest Expense 18.2m / Debt 1.02b)
Taxrate = 15.17% (22.3m / 147.2m)
NOPAT = 141.4m (EBIT 166.7m * (1 - 15.17%))
Current Ratio = 2.39 (Total Current Assets 5.66b / Total Current Liabilities 2.37b)
Debt / Equity = 0.25 (Debt 1.02b / totalStockholderEquity, last quarter 4.13b)
Debt / EBITDA = -10.01 (Net Debt -3.02b / EBITDA 301.3m)
Debt / FCF = -6.49 (Net Debt -3.02b / FCF TTM 464.6m)
Total Stockholder Equity = 3.68b (last 4 quarters mean from totalStockholderEquity)
RoA = 1.02% (Net Income 68.5m / Total Assets 7.63b)
RoE = 1.86% (Net Income TTM 68.5m / Total Stockholder Equity 3.68b)
RoCE = 4.36% (EBIT 166.7m / Capital Employed (Equity 3.68b + L.T.Debt 139.6m))
RoIC = 3.04% (NOPAT 141.4m / Invested Capital 4.65b)
WACC = 7.54% (E(37.67b)/V(38.69b) * Re(7.70%) + D(1.02b)/V(38.69b) * Rd(1.79%) * (1-Tc(0.15)))
Discount Rate = 7.70% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 100.0 | Cagr: 4.90%
[DCF Debug] Terminal Value 73.48% ; FCFF base≈464.6m ; Y1≈320.8m ; Y5≈162.0m
Fair Price DCF = 63.05 (EV 3.40b - Net Debt -3.02b = Equity 6.42b / Shares 101.8m; r=7.54% [WACC]; 5y FCF grow -36.24% → 2.90% )
EPS Correlation: 74.67 | EPS CAGR: 159.7% | SUE: 3.71 | # QB: 1
Revenue Correlation: 97.75 | Revenue CAGR: 65.40% | SUE: N/A | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.72 | Chg30d=+0.204 | Revisions Net=+0 | Analysts=4
EPS next Year (2026-12-31): EPS=6.34 | Chg30d=-0.105 | Revisions Net=-2 | Growth EPS=+85.8% | Growth Revenue=+21.5%